Novozymes Biopharma to Offer Drug-Album?in Conjugatio?n Platform in Collaborat?ion with ThioLogics
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
As part of the partnership, Novozymes' customers will be given valuable access to conjugation specialists, providing assurance that they will receive the highest level of support to design stable and efficacious drug candidates.
"Combining the benefits of Novozymes' and ThioLogics' technology platforms means that we can now work with more customers across a wider range of drug candidates," says Dermot Pearson, Marketing Director at Novozymes Biopharma. He continues, "Together we are creating new opportunities for customers by providing them with a single access point to link Novozymes' Veltis albumins and ThioLogics' conjugation platform, to improve their products.
Exclusively marketed through Novozymes Biopharma, the collaboration will allow Novozymes to apply its technology to molecules that are not amenable to a genetic fusion approach, such as synthesized peptides and small molecules in oncology and rheumatoid arthritis. Combining the advantages of the two technologies will enable the versatile modification of these therapeutic molecules to yield well-defined, stable and consistent conjugates.
"We are delighted to announce ThioLogics' unique collaboration with Novozymes, which will expand the capabilities of our technology platform beyond antibody drug conjugates," comments Dr Chris Williams, Business Development Manager at ThioLogics.
Professor Stephen Caddick, one of the Founders of ThioLogics said; "For the first time, the linking of our two platforms will make well-defined and stable albumin conjugation a reality, providing manufacturers with serum stable drug conjugates with tailored pharmacokinetics to maximize the therapeutic potential of their products.
Combining the Veltis platform with ThioLogics’ next generation maleimide technology, in addition to Novozymes' recently announced partnership with Almac, provides Veltis with a strong position in the field of drug conjugation and supports the use of the technology in peptide and protein fusion.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance